Mutational clonality and intratumour heterogeneity as biomarkers for cancer immunotherapy
26 Apr 2016
Mutational clonality and intratumour heterogeneity as biomarkers for cancer immunotherapy
Risk of breast cancer after chest radiotherapy may be affected by genetics
Retroviral replicating vectors for cancer-targeted gene therapy and immunotherapy
NY-ESO-1 immunotherapy for ovarian cancer
Imaging tumour habitats - life at the edge
Normal and neoplastic stem cells
WIN 2016: Preview of themes
WIN 2016: Preview of Speakers
Management of CLL patients in the front-line setting: live broadcast
Novel agents before and after stem cell transplantation for myeloma
Immunology highlights from the ITOC-3 conference
EBMT 2016 Highlights: Expert discussion